Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Arbourmarkon Dec 30, 2021 2:29pm
143 Views
Post# 34271647

Daily Manipulation Continues

Daily Manipulation ContinuesThis has been happening now for a month. It involves the same houses day in & day out. CIBC and Anonymous continue to trade via dark pool and at times 30% of daily volume traded via dark pool. This is not normal in my opinion for a stock that trades less then 100,000 shares daily. Dark pool trading was created for institutional traders to trade large blocks of shares to prevent spooking the market but that is not the case here. CIBC and Anonymous trades 100 share blocks via dark pool.

One would think with Covid-19 cases exploding and Arch fully funded for phase 3 trial waiting on Health Canada approval to commence the trial that share price would have held $5 or continued to gain and stabilize at levels that other phase 3 companies are market cap wise.

We hit a high of $5.30 and today we have hit $3.48 this is a 35% pullback. Daily Volume is consistently low due to tight float held by insiders.

The science is sound and the future is bright but it is gut wrenching to watch this slide 3-5% every day with whipsaw swings knocking it lower by 10-12% on a few thousand shares.
<< Previous
Bullboard Posts
Next >>